Posters

Comorbidity Burden and Characterization of Psoriasis (PsO)
Impact of Psoriasis Severity on Patient-reported Clinical Symptoms, QoL and Work Productivity

Comorbidity Burden and Characterization of Psoriasis (PsO) Patients with Concurrent Psoriatic Arthritis (PsA) in the Corrona Psoriasis Registry

Summary:
•Psoriasis (PsO) is an immune mediated chronic inflammatory disease with severe disease burden associated with several comorbidities and impact on quality of life. Psoriatic arthritis (PsA) is a spondyloarthritic condition, which is present in up to 42% of individuals with psoriasis. •Studies have shown that patients with psoriasis, PsA or both generally have poorer quality of life outcomes, work productivity and functionality similar to other serious diseases such as heart disease and diabetes. •The objective of this study is to characterize the PsO patients with psoriatic arthritis (PsA) and examine association of outcomes with PsAin the Corrona Psoriasis Registry, a large prospective registry that was launched in collaboration with the National Psoriasis Foundation (NPF) to study the comparative effectiveness, safety of approved systemic PsO therapies and treatment patterns in a real world setting.
Authors:
Bruce Strober, Chitra Karki, Marc Mason, Ning Guo, Jeffrey D Greenberg, Mark Lebwohl
PDF icon Download (782.07 KB)

Impact of Psoriasis Severity on Patient-reported Clinical Symptoms, Health-related Quality of Life, and Work Productivity Among US Patients: Real-world Data From the Corrona Psoriasis Registry

Summary:
•Psoriasis is a chronic, immune-mediated disease, with key clinical symptoms including skin itching, pain, and fatigue •Previous studies have reported that increased psoriasis severity is associated with worsened patient quality of life (QoL) and reduced work productivity1-5;however, few studies have examined how the severity measures used in clinical trials are associated with QoLin the real-world setting: oOne example of such a severity measure is the Investigator’s Global Assessment (IGA) mod 2011, which has been used in clinical trials7 oAffected body surface area (BSA) is a severity measure that is widely used by physicians •The objective of this study is to gain a better understanding of the relationship between disease severity in terms of IGA and BSA and patient-reported outcomes in a real-world setting
Authors:
B. Strober, J.D. Greenberg, C. Karki, M. Mason, N. Guo, P. Hur, Y. Zhao, V. Herrera, F. Lin, M. Lebwohl
PDF icon Download (439.28 KB)